Aemetis Stock Forecast, Price & News

Aemetis (NASDAQ:AMTX) Frequently Asked Questions

Is Aemetis a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aemetis stock.
View analyst ratings for Aemetis or view top-rated stocks.

How has Aemetis' stock been impacted by Coronavirus (COVID-19)?

Aemetis' stock was trading at $0.6511 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMTX shares have increased by 1,264.6% and is now trading at $8.8850.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aemetis?

Aemetis saw a increase in short interest in December. As of December 31st, there was short interest totaling 4,500,000 shares, an increase of 25.7% from the December 15th total of 3,580,000 shares. Based on an average daily volume of 840,100 shares, the days-to-cover ratio is currently 5.4 days. Currently, 16.9% of the company's shares are short sold.
View Aemetis' Short Interest.

When is Aemetis' next earnings date?

Aemetis is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Aemetis.

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) announced its quarterly earnings data on Thursday, November, 11th. The specialty chemicals company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.25. The specialty chemicals company had revenue of $49.90 million for the quarter, compared to analyst estimates of $54.23 million. During the same quarter in the previous year, the firm posted ($0.59) earnings per share.
View Aemetis' earnings history.

What price target have analysts set for AMTX?

6 brokers have issued 12 month price objectives for Aemetis' shares. Their forecasts range from $25.00 to $33.00. On average, they expect Aemetis' stock price to reach $29.25 in the next twelve months. This suggests a possible upside of 229.2% from the stock's current price.
View analysts' price targets for Aemetis or view top-rated stocks among Wall Street analysts.

Who are Aemetis' key executives?

Aemetis' management team includes the following people:

• Eric Armstrong McAfee, Chairman & Chief Executive Officer
• Todd A. Waltz, Chief Financial Officer, Secretary & Executive VP
• Andrew B. Foster, Executive Vice President (LinkedIn Profile)
• Sanjeev Gupta, President-Aemetis International

Who are some of Aemetis' key competitors?

Some companies that are related to Aemetis include Westlake Chemical Partners (WLKP), Origin Materials (ORGN), Gevo (GEVO), Cyclo Therapeutics (CTDH), REX American Resources (REX), Green Plains Partners (GPP), Alto Ingredients (ALTO), FutureFuel (FF), SolarWindow Technologies (WNDW), Image Chain Group (ICGL), Cyclo Therapeutics (CYTH), Sino United Worldwide Consolidated (SUIC), American Energy Partners (AEPT), TOMI Environmental Solutions (TOMZ) and Tantech (TANH).
View all of AMTX's competitors.

What other stocks do shareholders of Aemetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aemetis investors own include Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), Cannabics Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Tilly's (TLYS), Auxly Cannabis Group (CBWTF), Novan (NOVN), Aeterna Zentaris (AEZS), American Cannabis (AMMJ) and Bionano Genomics (BNGO).

What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Who are Aemetis' major shareholders?

Aemetis' stock is owned by a number of retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%), Russell Investments Group Ltd. (0.18%) and Spire Wealth Management (0.01%). Company insiders that own Aemetis stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Sanjeev Gupta, Timothy Alan Simon and Todd Waltz.
View institutional ownership trends for Aemetis.

Which institutional investors are buying Aemetis stock?

AMTX stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP, Russell Investments Group Ltd., and Spire Wealth Management.
View insider buying and selling activity for Aemetis or or view top insider-buying stocks.

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $8.89.

How much money does Aemetis make?

Aemetis has a market capitalization of $295.44 million and generates $165.56 million in revenue each year. The specialty chemicals company earns $-36.66 million in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does Aemetis have?

Aemetis employs 164 workers across the globe.

What is Aemetis' official website?

The official website for Aemetis is www.aemetis.com.

Where are Aemetis' headquarters?

Aemetis is headquartered at 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at [email protected], or via fax at 408-252-8044.